The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 11, 2022
Filed:
Jun. 30, 2017
Applicant:
Cellectis, Paris, FR;
Inventors:
Jean-Pierre Cabaniols, Saint Lau la Foret, FR;
Jean-Charles Epinat, Les Lilas, FR;
Philippe Duchateau, Draveil, FR;
Assignee:
CELLECTIS, Paris, FR;
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); C12N 5/0783 (2010.01); C12N 9/22 (2006.01); C12N 13/00 (2006.01); C12N 15/113 (2010.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); C12N 5/0636 (2013.01); C12N 9/22 (2013.01); C12N 13/00 (2013.01); C12N 15/113 (2013.01); C12N 15/902 (2013.01); C12N 2310/20 (2017.05); C12N 2510/00 (2013.01); C12N 2800/80 (2013.01);
Abstract
The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.